(ACCORD, BARI 2D, VADT, and Look AHEAD) explore outcomes of various therapeutic regimens on cardiovascular morbidity and mortality in established T2DM. The other four studies (ORIGIN, NAVIGATOR, DREAM, and ADOPT) evaluate whether aggressive treatment options can delay the onset and/or progression of pre-diabetes or early T2DM and the effects on cardiovascular risk factors. ORIGIN and NAVIGATOR are sufficiently powered to give us definitive answers on hard outcomes on cardiovascular events. Over the next 5 to 10 years, these research outcomes will likely change the face of T2DM.

We hope you find this information valuable. You are invited to use the slides and notecards for incorporation into your own educational presentations.

References
Click on the reference to view the abstract online.

Abraira C, Duckworth W, McCarren M, et al, for the participants of the VA Cooperative Study of Glycemic Control and Complications in Diabetes Mellitus. Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial. J Diabetes Complications. 2003;17:314-322.

The Look AHEAD Research Group. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control ClinTrials. 2003;24:610-628.

Viberti G, Kahn SE, Greene DA, et al. A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care. 2002;25:1737-1743.

Type 2 Diabetes Outcomes Trials On The Horizon

Rapid advances have been made in our knowledge of type 2 diabetes (T2DM) management since the 1998 publication of the United Kingdom Prospective Diabetes Study (UKPDS). In the past 2 years alone, large-scale trials such as the Diabetes Prevention Program (DPP) and the Steno-2 study have shown us that the development of T2DM can be delayed and its major complications prevented through early, aggressive, multifactorial treatment.

However, there is still much we do not know. The impact of long-term, intensive glycemic control on cardiovascular (CV) outcomes remains unclear. Effective strategies to halt the seemingly irreversible decline of b-cell function have yet to be identified. The efficacy of alternative interventions to prevent or delay the development of T2DM needs to be explored.

Numerous studies are currently being conducted to address these questions, and within 5 to 10 years, these research outcomes will lead to significant changes in how every practitioner diagnoses and treats T2DM. This Reprint Lecture Kit has been designed to provide practitioners with a comprehensive, early introduction to the designs, methodologies, and study questions of eight studies currently under way.